1)国立がん研究センターがん統計・がん情報サービス.乳房.https://ganjoho.jp/reg_stat/statistics/stat/cancer/14_breast.html
2)Momozawa Y, et al : Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. Nat Commun 9 : 4083, 2018
3)Kuchenbaeker KB,et al : Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317 : 2402-2416, 2017
4)Moore K, et al : Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379 : 2495-2505, 2018
5)González-Martín A, et al : Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381 : 2391-2402, 2019
6)Ray-Coquard I, et al : Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381 : 2416-2428, 2019
7)Pujade-Lauraine E,et al : Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation(SOLO2/ENGOT-Ov21) : a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18 : 1274-1284, 2017
8)Mirza MR, et al : Niraparib maintenance therapy in platinum- sensitive, recurrent ovarian cancer. N Engl J Med 375 : 2154-2164, 2016
9)NCCN Clinical Practice Guidelines in Oncology. Genetic/Familial High-Risk Assessment : Breast, Ovarian, and Pancreatic. version 1, 2023, September 7, 2022
10)Domchek SM, et al : Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304 : 967-975, 2010
11)Rebbeck TR, et al : Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101 : 80-87, 2009
12)Sekine M, et al : Differences in age at diagnosis of ovarian cancer for each BRCA mutation type in Japan : optimal timing to carry out risk-reducing salpingo-oophorectomy. J Gynecol Oncol 33 : e46, 2022
13)日本婦人科腫瘍学会 がんゲノム医療,HBOC診療の適性化に関するワーキンググループ(委員長 : 青木大輔) : 産婦人科における遺伝性乳がん卵巣がん症候群に対する保険診療についての考え方.2020年4月6日(2021年6月11日改訂) https://jsgo.or.jp/opinion/05.html
14)JOHBOC(日本遺伝性乳癌卵巣癌総合診療制度機構)(編) : 遺伝性乳癌卵巣癌(HBOC)診療ガイドライン2021年版.金原出版,2021
15)Shu CA, et al : Uterine cancer after risk―reducing salpingo―oophorectomy without hysterectomy in women with brca mutations. JAMA Oncol 2 : 1434-1440, 2016
16)Steenbeek MP et al : Risk of peritoneal carcinomatosis after risk-reducing salpingo-oophorectomy : a systematic review and Individual patient data meta-analysis. J Clin Oncol 40 : 1879-1891, 2022
17)日本乳がん学会(編) : 乳癌診療ガイドライン治療編2022年度版.金原出版,2022